Chimeric, Mutated, Or Recombined Hybrid (e.g., Bifunctional, Bispecific, Rodent-human Chimeric, Single Chain, Rfv, Immunoglobulin Fusion Protein, Etc.) Patents (Class 530/387.3)
  • Patent number: 10675352
    Abstract: Extracellular drug conjugates (EDCs) targeting CD38 are useful in the treatment of diseases such as cancer and immune disorders, including asthma.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: June 9, 2020
    Assignee: Centrose, LLC
    Inventor: James R. Prudent
  • Patent number: 10669337
    Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: June 2, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Bryan Allen Irving, Sherry Lynn La Porte, Jason Gary Sagert, Daniel Robert Hostetter, Olivia Jennifer Razo, Clayton William White, Jennifer Hope Richardson
  • Patent number: 10640562
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: May 5, 2020
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • Patent number: 10603303
    Abstract: The invention provides methods of treating or preventing an ocular disease or disorder in a subject, methods of treating or preventing ocular pain or discomfort comprising, administering to the subject a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a transient receptor potential melastatin 8 (TRPM8) antagonist. In certain preferred embodiments, the ocular disease or disorder is a dry eye disease.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: March 31, 2020
    Assignee: Ora, Inc.
    Inventors: Mark B. Abelson, Peter Corcoran, Keith Lane
  • Patent number: 10577418
    Abstract: The present application is directed to an invention based on the discovery that the BLCA-38 antibody is actually an antibody population comprising two distinct monoclonal antibodies. The claims define an isolated antibody population comprising first antibodies and/or antigen binding fragments thereof defined by specific heavy chain and light chain variable regions and wherein the antibody population does not contain second antibodies defined by specific light chain variable regions. The claims also define hybridoma cells, cultures capable of producing such antibody populations, compositions comprising such antibody populations, nucleic acid molecules encoding such antibodies, vectors, host cells thereof, and processes for production of the antibody populations of the invention.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: March 3, 2020
    Assignee: Minomic International LTD.
    Inventors: Douglas Campbell, Irene Justiniano Fuenmayor, Aline Nocon, Julie Soon, Quach Truong, Bradley Walsh, Sandra Wissmueller
  • Patent number: 10570196
    Abstract: The disclosure provides methods of treating tauopathies (e.g. Alzheimer's disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia with Parkinsonism linked to chromosome 17, Pick's Disease, Progressive Supranuclear Palsy, Dementia Pugilistica, Down's Syndrome and others) by administering humanized antibodies. The disclosure also provides the anti-tau humanized antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes).
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 25, 2020
    Inventor: Anahit Ghochikyan
  • Patent number: 10570208
    Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-? and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: February 25, 2020
    Assignee: Baylor Research Institute
    Inventors: Yong-Jun Liu, Sandra Zurawski, SangKon Oh, Shino Hanabuchi, Haruyuki Fujita, Hideki Ueno, Patrick Blanco, Hyemee Joo
  • Patent number: 10556942
    Abstract: The present invention relates to the purification of TNFR:Fc fusion protein. More specifically related to process of purification of TNFR:Fc fusion protein wherein the HCP is reduced. The present invention is directed to the use of mixed-mode chromatography and/or affinity chromatography to produce TNFR:Fc fusion protein which is substantially free of at least one of the protein degrading enzyme present in HCP.
    Type: Grant
    Filed: June 13, 2015
    Date of Patent: February 11, 2020
    Assignee: LUPIN LIMITED
    Inventors: Abir Banerjee, Chandranath Ganapathy, Sorab Rustom Mody, Ashok Mishra
  • Patent number: 10525130
    Abstract: The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: January 7, 2020
    Assignee: Sanofi
    Inventors: Julia Schnieders, Dirk Usener, Sabrina Ruggeberg, Ahmed Youssef, Martina Kirsch, Annika Hagendorf
  • Patent number: 10526397
    Abstract: The invention provides modifications within human or humanized single domain antibody fragments (sdAbs) that prevent recognition by pre-existing antibodies, to isolated polypeptides that include these modifications, and to methods and uses thereof.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: January 7, 2020
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Quinn Deveraux
  • Patent number: 10517929
    Abstract: Provided herein are pharmaceutical compositions, formulations and dosage forms comprising variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). Methods of using the pharmaceutical compositions, formulations and dosage forms are also provided herein.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: December 31, 2019
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Darrin Anthony Lindhout, Charles V. Olson
  • Patent number: 10519247
    Abstract: The disclosure provides monoclonal bispecific antibodies targeting HER2 and HER3. The disclosure also provides monospecific tetravalent HER3 antigen binding antibodies. Still further provided by the disclosure are methods of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody provided by the disclosure.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: December 31, 2019
    Assignee: Board of Regents,The University of Texas System
    Inventors: E. Sally Ward, Raimund Ober, Jeffrey Kang, Jayakumar Poovassery
  • Patent number: 10501558
    Abstract: Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: December 10, 2019
    Assignee: Sutro Biopharma, Inc.
    Inventors: Christopher D. Thanos, Leslie McEvoy, Gang Yin, Kalyani Penta, Ramesh Baliga, Sunil Bajad, Sonia Pollitt, Chris Murray, Alex Steiner, Avinash Gill
  • Patent number: 10494440
    Abstract: Provided herein are methods for promoting neurogenesis in neural tissue of a patient exhibiting at least one symptom of a central nervous system disorder, the method comprising administering to a subject in need thereof an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 3, 2019
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Maurice Zauderer
  • Patent number: 10494599
    Abstract: The invention is comprised within automated devices for cell culture. The invention relates to a cell culture method and system which allows modifying in a controlled manner the density and the number of cells in a culture. Specifically, the present invention relates to an iterative method the number of iteration steps of which is modified depending on the demand for the density and the number of cells necessary for the culture duration.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: December 3, 2019
    Assignee: ALGARIS CELL S.L.
    Inventors: David Horna Tomas, Miguel Costa Ferrando
  • Patent number: 10487156
    Abstract: The present invention relates to multispecific antibodies, for example bispecific antibodies, and methods for the isolation or purification of the same. The antibodies of the invention comprise first and second heavy chain-light chain pairings wherein each pairing comprises a distinct selective recognition site including one or more amino acid residues contributed from the heavy chain and the light chain of the pairing. The first and second selective recognition sites differ by at least one amino acid residue and can be differentially bound by first and second selective recognition agents according to the methods of the invention. Such methods facilitate the production of antibody preparations enriched for multispecific antibodies having the correct functional heavy chain-light chain pairings.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: November 26, 2019
    Assignee: argenx BVBA
    Inventors: Christophe Frederic Jerome Blanchetot, Johannes Joseph Wilhelmus De Haard
  • Patent number: 10487151
    Abstract: Disclosed herein are methods and compositions related to antibody fragments which specifically bind sialyl-Tn epitope of tumor-associated glycoprotein 72 (TAG-72).
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 26, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Thomas J. Magliery, Brandon J. Sullivan, Nicholas E. Long
  • Patent number: 10471099
    Abstract: Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: November 12, 2019
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Harvey Lodish, Hidde L. Ploegh, Hsiang-Ying Lee, Jiahai Shi, Lenka Hoffman, Novalia Pishesha
  • Patent number: 10457748
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I): (Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III): V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, n independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V and V2, in particular where a disulphide bond is present.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 29, 2019
    Inventors: Emma Dave, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 10457749
    Abstract: The invention relates to the purification of bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule from a mixture of monospecific antibodies. The bispecific antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain. This invention in particular relates to the isolation of these bispecific antibodies from mixtures that contain monospecific antibodies having two Kappa light chains or portions thereof and monospecific antibodies having two Lambda light chains or portions thereof. The invention also provides the methods of efficiently purifying these bispecific antibodies.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: October 29, 2019
    Assignee: NovImmune SA
    Inventors: Nicolas Fouque, Jean François Depoisier, Keith Wilson, Judith Vajda, Egbert Müller, Romain Dabre
  • Patent number: 10392438
    Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: August 27, 2019
    Assignee: PFIZER INC.
    Inventors: Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
  • Patent number: 10377833
    Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: August 13, 2019
    Assignee: Beijing Mabworks Biotech Co., Ltd.
    Inventors: Feng Li, Boyan Zhang, Pei Ye, Jian Zhao, Sijia Huang, Chunyang Jin
  • Patent number: 10357571
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: July 23, 2019
    Assignees: Thomas Jefferson University, City of Hope
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
  • Patent number: 10351630
    Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of DPP-4 levels in samples obtained from human patients. The disclosure further provides novel anti-DPP-4 monoclonal antibodies that recognize human DPP-4, and assay kits comprising one or more of these antibodies.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: July 16, 2019
    Assignee: MEDIMMUNE, LLC
    Inventors: Chien-Ying Chang, Xiaodong Xiao, Partha Chowdhury
  • Patent number: 10344067
    Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 9, 2019
    Inventors: Guy Ungerechts, Christine Engeland, Ruta Veinalde
  • Patent number: 10342869
    Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: July 9, 2019
    Inventors: Byron C. Hann, Blake Tomkinson, Thomas G. Martin, III, Blake T. Aftab
  • Patent number: 10316084
    Abstract: The invention provides anti-LgR5 antibodies and methods of using the same.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: June 11, 2019
    Assignee: GENENTECH, INC.
    Inventors: Andrew G. Polson, Weiguang Mao, Ron Firestein
  • Patent number: 10294296
    Abstract: Administration of a mAb that specifically binds IL-1? is useful for treating tumor-associated diseases in human subjects.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: May 21, 2019
    Assignee: XBiotech, Inc.
    Inventor: John Simard
  • Patent number: 10273299
    Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: April 30, 2019
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Arthur E. Frankel, Yunpeng Su, Brad St. Croix, Stephen H. Leppla
  • Patent number: 10273281
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: April 30, 2019
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
  • Patent number: 10266578
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 23, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Patent number: 10261083
    Abstract: The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: April 16, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 10253091
    Abstract: By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: April 9, 2019
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Taichi Kuramochi, Atsuhiko Maeda, Hirotake Shiraiwa
  • Patent number: 10251377
    Abstract: The present invention relates to humanisation of antibodies in vivo. The invention provides non-human vertebrates, cells, populations and methods useful for humanising chimaeric antibodies in vivo. Using the present invention it is possible straightforwardly and rapidly to obtain antigen-specific antibodies that are fully human (ie, comprising human variable and constant regions) and have undergone recombination, junctional diversification, affinity maturation and isotype switching in vivo in a non-human vertebrate system. Furthermore, such antibodies are humanised (eg, totally human)—and selected—totally in vivo, and as such the present invention harnesses in vivo filtering for expressibility, affinity and biophysical characteristics in the context of the desired human variable and constant region pairings. This is avoids problems of down-grading antibody characteristics when humanising the constant region of chimaeric antibodies in vitro.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: April 9, 2019
    Assignee: Kymab Limited
    Inventor: Jasper Clube
  • Patent number: 10239951
    Abstract: Described herein are isolated bi-specific antigen binding constructs, e.g., antibodies. The bi-specific antigen binding constructs include two antigen binding polypeptide constructs, e.g., a Fab and an scFv. The first antigen-binding polypeptide construct monovalently and specifically binds to extracellular domain 4 (ECD4) of HER2 (human epidermal growth factor receptor 2); the second antigen-binding polypeptide construct monovalently and specifically binds to an extracellular domain (ECD) of HER3 (human epidermal growth factor receptor 3). One antigen binding polypeptide construct is a Fab format and the other antigen binding polypeptide construct is an scFv format. The bi-specific antigen binding constructs includes an Fc having two Fc polypeptides each having a CH3 domain for dimerization. Each Fc polypeptide is linked to the C-terminus of one of the antigen binding polypeptide constructs with or without a linker.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: March 26, 2019
    Assignee: Zymeworks Inc.
    Inventors: Gordon Yiu Kon Ng, Peter Wing Yiu Chan, Grant Raymond Wickman
  • Patent number: 10233220
    Abstract: Anti-tumor immune responses to modified self-epitopes. The present invention relates to the use of tumor-associated epitopes in medicine and in particular in the treatment of cancer. The epitopes stimulate an immune reaction against the tumor and have a modification selected from deimination of arginine to citrulline, nitration of tyrosine, oxidation of tryptophan and deamination of glutamine or asparagine. The invention also relates to nucleic acids comprising sequences that encode such epitopes for use in the treatment of cancer.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: March 19, 2019
    Assignee: Scancell Limited
    Inventors: Linda Gillian Durrant, Victoria Anne Brentville, Rachael Louise Metheringham
  • Patent number: 10233237
    Abstract: The present application is directed to heterodimeric antibodies and methods of use.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 19, 2019
    Assignee: AMGEN INC.
    Inventors: Gunasekaran Kannan, Monica Florio, Zhi Liu, Wei Yan
  • Patent number: 10220081
    Abstract: The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., LIGHT polypeptide sequence) that bind to the HVEM cis complexes.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: March 5, 2019
    Inventors: Carl F. Ware, Timothy C. Cheung, Marcos Steinberg
  • Patent number: 10196442
    Abstract: Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of treating cancer with such antibodies.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 5, 2019
    Assignee: Bionomics Inc.
    Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Christilyn Graff, Weixing Yang
  • Patent number: 10196437
    Abstract: Provided are: an antibody binding specifically to a surface antigen, pre-S1, of a hepatitis B virus (HBV); a polynucleotide coating the antibody; an expression vector comprising the polynucleotide; a transformation agent comprising the expression vector; and use of the antibody in treating or preventing HBV infection and in detecting an HBV.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: February 5, 2019
    Inventors: Hyo Jeong Hong, Jin Hong Kim
  • Patent number: 10196453
    Abstract: Clostridium difficile is the most common hospital acquired pathogen in the United States, and infection is in many cases fatal. Toxins A and B are its major virulence factors, but increasingly a third toxin may be present, known as C. difficile transferase (CDT). An ADP-ribosyltransferase that causes actin cytoskeletal disruption, CDT is typically produced by the major, hypervirulent strains and has been associated with more severe disease. It is disclosed herein that CDT enhances the virulence of two PCR-ribotype 027 strains in mice. The toxin induces pathogenic host inflammation via a novel Toll-like Receptor 2 (TLR2) dependent pathway, resulting in the suppression of a protective host eosinophilic response. Finally, it is disclosed that restoration of TLR2 deficient eosinophils is sufficient for protection from a strain producing CDT. These findings offer an explanation for the enhanced virulence of CDT-expressing C.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: February 5, 2019
    Assignee: University of Virginia Patent Foundation
    Inventors: Carrie Adeline Cowardin, William A. Petri, Jr.
  • Patent number: 10179819
    Abstract: The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: January 15, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jessica R. Kirshner, Alison Crawford, Gavin Thurston, Eric Smith, Lauric Haber, Drew Dudgeon, Ashique Rafique
  • Patent number: 10174114
    Abstract: The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: January 8, 2019
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang
  • Patent number: 10167334
    Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
    Type: Grant
    Filed: April 3, 2016
    Date of Patent: January 1, 2019
    Inventors: Amer M. Mirza, Rosemary J. Akhurst, Ou Li
  • Patent number: 10138293
    Abstract: The present invention relates to nucleic acids which encode the heavy chains and light chains of a novel domain exchanged, bivalent, bispecific antibody, and vectors comprising the same.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: November 27, 2018
    Inventors: Christian Klein, Wolfgang Schaefer
  • Patent number: 10130721
    Abstract: A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: November 20, 2018
    Assignee: Immunocore Limited
    Inventors: Bent Karsten Jakobsen, Annelise Brigitte Vuidepot, Yi Li
  • Patent number: 10117949
    Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: November 6, 2018
    Inventors: Haitao Wang, Yong Du, Rui Zhang, Jing Xu, Longbin Liu
  • Patent number: 10106612
    Abstract: Herein is reported a method for producing a bispecific antibody comprising the step of incubating (i) an antibody Fab fragment or a scFv antibody comprising within the 20 C-terminal amino acid residues the amino acid sequence LPX1TG (SEQ ID NO: 01), (ii) a one-armed antibody comprising a full length antibody heavy chain, a full length antibody light chain, and an Fc-heavy chain, whereby the full length antibody heavy chain and the full length antibody light chain are cognate antibody chains that thereof forms an antigen binding site, whereby the full length antibody heavy chain and the Fc-heavy chain are covalently linked to each other via one or more disulfide bonds forming an antibody hinge region, and whereby the Fc-heavy chain has an oligoglycine amino acid sequence at its N-terminus, and (iii) a Sortase A enzyme.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: October 23, 2018
    Inventors: Sebastian Fenn, Erhard Kopetzki, Georg Tiefenthaler
  • Patent number: RE47194
    Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p ??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: January 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Jagath R. Junutula, William Mallet
  • Patent number: RE47223
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 5, 2019
    Assignee: GENENTECH, INC.
    Inventors: Mark S. Dennis, Paul Polakis, William Mallet